Sonrotoclax demonstrated a total overall response rate of 52%, including a complete response rate of 16%. However, Wang ...

Managed care organizations must prioritize dextromethorphan-bupropion based on sustained efficacy, improved remission rates, ...

At ASH 2025, sonrotoclax demonstrated encouraging response rates and a favorable safety profile as a single-agent BCL2 ...

Intravenous (IV) and subcutaneous (SC) formulations each play important roles in modern oncology care, with distinct ...

Explore the latest advancements in HER2-positive breast cancer treatments, highlighting the promising results of DESTINY-Breast trials for improved patient outcomes.

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet clinical need remains overcoming late and misdiagnosis through targeted ...

Discover how advancements in HER2-positive breast cancer treatment enhance patient outcomes through personalized therapies and innovative strategies for both early and metastatic stages.

Strong adherence and safety. Long-term cost savings depend heavily on patient adherence. While twice-daily dosing may pose some risk, its safety profile and novel mechanism—targeting NMDA and sigma-1 ...

Following the clinical success of new agents like nerandomilast, the next critical steps for managing ILD involve dismantling financial and geographical barriers to access, and rigorously integrating ...

The FDA approved oral semaglutide (Wegovy) for weight loss and reducing major adverse cardiovascular events. Novo Nordisk ...

Expanding bispecific antibody access for multiple myeloma involves collaboration between academic centers and community ...

AI innovations, such as the ASCO Guidelines Assistant, enhance evidence-based decision-making by providing quick access to ...